Prospective Pilot Study of Pre-Transplant Thymoglobulin Administration in Living Donor Renal Transplant Recipients

This study has been completed.
Genzyme, a Sanofi Company
Information provided by (Responsible Party):
E. Steve Woodle, University of Cincinnati Identifier:
First received: October 10, 2008
Last updated: December 15, 2015
Last verified: December 2015
To determine how safe and effective giving Thymoglobulin before transplantation to patients who are going to be receiving kidney transplants.

Condition Intervention Phase
Renal Transplant Rejection
Transplants and Implants
Drug: Thymoglobulin
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Prospective, Single Center, Pilot Study of Pretransplant Thymoglobulin Administration and Early Corticosteroid Withdrawal in Living Donor Renal Transplant Recipients Under Mycophenolate Mofetil (MMF) and Tacrolimus Immunosuppression

Resource links provided by NLM:

Further study details as provided by University of Cincinnati:

Primary Outcome Measures:
  • Composite End Point of Acute Rejection, Graft Loss or Patient Death [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Proportion of Patients Meeting the Composite End Point of Acute Rejection, Graft loss or Patient death

Secondary Outcome Measures:
  • Incidence of Treatment Failures: Defined as the Percentage of Patients That do Not Remain on Initial Therapy. [ Time Frame: Ongoing ] [ Designated as safety issue: No ]
  • Incidence of Infections [ Time Frame: Not defined ] [ Designated as safety issue: No ]
  • Need for Antilymphocyte Antibody Therapy to Treat Acute Rejection [ Time Frame: Not defined ] [ Designated as safety issue: No ]
  • Severity of Biopsy-proven Rejection Using Banff 97 Criteria [ Time Frame: Not defined ] [ Designated as safety issue: No ]
  • Serum Creatinine [ Time Frame: Post-operative days 1-7, 30, 90 and 6 months ] [ Designated as safety issue: No ]
  • Malignancy [ Time Frame: Undefined ] [ Designated as safety issue: Yes ]

Enrollment: 11
Study Start Date: September 2008
Study Completion Date: July 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: rATG 4 doses
Preloading Induction with Thymoglobulin® X 4 doses given day -4, day -2, day 0, and day 2 at 1.5 mg/kg/dose + corticosteroid taper + tacrolimus + MMF
Drug: Thymoglobulin
Preloading Induction with Thymoglobulin® X 4 doses given day -4, day -2, day 0, and day 2 at 1.5 mg/kg/dose + corticosteroid taper + tacrolimus + MMF
Other Names:
  • Anti-thymocyte globulin (rabbit), thymoglobulin
  • rATG
Active Comparator: rATG 3 doses
Preloading Induction with Thymoglobulin® X 3 doses given day -4 (1.5mg/kg), day -2 (1.5mg/kg), and day 0 (3mg/kg) + corticosteroid taper + tacrolimus + MMF
Drug: Thymoglobulin
Preloading Induction with Thymoglobulin® X 3 doses given day -4 (1.5mg/kg), day -2 (1.5mg/kg), and day 0 (3mg/kg) + corticosteroid taper + tacrolimus + MMF
Other Names:
  • anti-thymocyte globulin (rabbit), thymoglobulin
  • rATG

Detailed Description:
We will evaluate the therapeutic efficacy of administering Thymoglobulin® induction pre-transplantation in renal allograft recipients. Patients receiving pre-transplant Thymoglobulin will be evaluated for acute rejection (Banff '97 criteria), survival, and safety at 6 months. Overall the use of Thymoglobulin induction pre-transplantation will be safe and effective.

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Adult living donor renal transplant recipient.
  2. Patient is at least 18 years of age
  3. If female and of childbearing potential, have a negative serum or urine HCG within 24 hours prior to Study Day -5 (Day of 1st Thymoglobulin dose) and must practice a medically approved method of birth control for the past 30 days prior to enrollment and agree to continue this practice during the 6 month efficacy analysis.
  4. Signed informed consent.

Exclusion Criteria:

  1. Human Leukocyte Antibody (HLA) identical living donor transplant recipient.
  2. History of a positive cross-match with the donor.
  3. Patients with a peak CDC PRA > 50% or a current CDC PRA > 25%.
  4. Patients who have previously received a kidney transplant.
  5. Active donor or recipient serology positive for human immunodeficiency virus (HIV), Hepatitis B virus (HBV), or Hepatitis C virus (HCV).
  6. History of noncompliance.
  7. History of chronic corticosteroid or immunosuppressive use except for inhaled corticosteroids to treat asthma. .
  8. Multiple organ transplant recipient.
  9. Patient with a urinary bladder that is absent or not functional (e.g. self catheterization) pretransplant.
  10. Patient who does not agree to use effective birth control during the 6-month efficacy analysis.
  11. Known contraindication to administration of rabbit antithymocyte globulin.
  12. Initial screening laboratory evaluations will be done locally before renal transplantation and the following laboratory values will be exclusionary: Platelets < 100,000/mm23 or WBC < 3000/mm3
  13. Currently abusing drugs or alcohol or, in the opinion of the investigator, is at high risk for poor compliance.
  14. Patient who, in the opinion of the investigator, has significant medical or psychosocial problems or unstable disease states that would preclude participation in the study. Examples of significant problems include, but are not limited to, morbid obesity or severe cardiac disease.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00771745

United States, Ohio
The Christ Hospital
Cincinnati, Ohio, United States, 45219
Sponsors and Collaborators
University of Cincinnati
Genzyme, a Sanofi Company
Principal Investigator: E. Steve Woodle, MD University of Cincinnati
Principal Investigator: Adele Rike, PharmD The Christ Hospital
  More Information

Responsible Party: E. Steve Woodle, MD, FACS, University of Cincinnati Identifier: NCT00771745     History of Changes
Other Study ID Numbers: Pre-Tx Thymo 
Study First Received: October 10, 2008
Results First Received: January 18, 2013
Last Updated: December 15, 2015
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Antilymphocyte Serum
Calcineurin Inhibitors
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs processed this record on May 30, 2016